Results 1 to 10 of about 1,282,878 (301)

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. [PDF]

Proceedings of the National Academy of Sciences, 1993
It has been reported that soluble interleukin (IL)-6 receptor (sIL-6R) is detected in the serum of healthy individuals and its level is increased in patients with multiple myeloma and human immunodeficiency virus infection. Although several reports have suggested that sIL-6R potentiates IL-6 action, its physiological role remains unclear. In this study,
T, Tamura, N, Udagawa, N, Takahashi, C, Miyaura, S, Tanaka, Y, Yamada, Y, Koishihara, Y, Ohsugi, K, Kumaki, T, Taga   +9 more
openaire   +3 more sources

Stabilized Interleukin-6 receptor binding RNA aptamers [PDF]

RNA Biology, 2013
Interleukin-6 (IL-6) is a multifunctional cytokine that is involved in the progression of various inflammatory diseases, such as rheumatoid arthritis and certain cancers; for example, multiple myeloma or hepatocellular carcinoma. To interfere with IL-6-dependent diseases, targeting IL-6 receptor (IL-6R)-presenting tumor cells using aptamers might be a ...
Cindy, Meyer, Katharina, Berg, Katja, Eydeler-Haeder, Inken, Lorenzen, Joachim, Grötzinger, Stefan, Rose-John, Ulrich, Hahn   +6 more
openaire   +3 more sources

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study [PDF]

Annals of the Rheumatic Diseases, 2013
Objectives The interleukin-6 receptor (IL-6R) blocker tocilizumab (TCZ) reduces inflammatory disease activity in rheumatoid arthritis (RA) but elevates lipid concentrations in some patients.
I. McInnes, L. Thompson, J. Giles, J. Bathon, J. Salmon, A. Beaulieu, C. Codding, T. Carlson, C. Delles, J. Lee, N. Sattar   +10 more
semanticscholar   +3 more sources

Interleukin-6 Receptor Subunit Alpha [PDF]

Definitions, 2020
openaire   +2 more sources

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

medRxiv, 2021
Background: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods: We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform ...
A. Gordon, P. Mouncey, Farah Al-Beidh, K. Rowan, A. Nichol, Y. Arabi, D. Annane, A. Beane, Wilma van Bentum-Puijk, L. Berry, Zahra Bhimani, M. Bonten, C. Bradbury, F. Brunkhorst, Adrian Buzgau, A. Cheng, M. Detry, E. J. Duffy, L. Estcourt, M. Fitzgerald, H. Goossens, R. Haniffa, A. Higgins, T. Hills, Christopher M. Horvat, F. Lamontagne, P. Lawler, H. Leavis, K. Linstrum, E. Litton, E. Lorenzi, J. Marshall, F. Mayr, D. McAuley, A. McGlothlin, S. McGuinness, B. McVerry, S. Montgomery, S. Morpeth, S. Murthy, Katrina Orr, R. Parke, Jane C. Parker, A. Patanwala, V. Pettilä, E. Rademaker, Marlene S. Santos, Christina T. Saunders, C. Seymour, M. Shankar-Hari, W. Sligl, A. Turgeon, Anne M Turner, F. L. van de Veerdonk, R. Zarychanski, Cameron Green, R. Lewis, D. Angus, C. McArthur, S. Berry, S. Webb, L. Derde   +61 more
semanticscholar   +1 more source

Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.

Journal of the American College of Cardiology, 2021
BACKGROUND Prompt myocardial revascularization with percutaneous coronary intervention (PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI).
K. Broch, A. K. Anstensrud, S. Woxholt, K. Sharma, I. Tøllefsen, B. Bendz, S. Aakhus, T. Ueland, B. Amundsen, J. Damås, E. S. Berg, E. Bjørkelund, C. Bendz, E. Hopp, Ola Kleveland, K. Stensæth, A. Opdahl, N. Kløw, I. Seljeflot, G. Andersen, R. Wiseth, P. Aukrust, L. Gullestad   +22 more
semanticscholar   +1 more source

Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context

The Lancet Respiratory Medicine, 2021
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 signalling in patients with the disease.
F. Angriman, B. Ferreyro, L. Burry, E. Fan, N. Ferguson, S. Husain, S. Keshavjee, E. Lupia, L. Munshi, Samuele Renzi, O. G. Ubaldo, B. Rochwerg, L. Del Sorbo   +12 more
semanticscholar   +1 more source

Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome

Cell Reports Medicine, 2021
Summary Data suggest that interleukin (IL)-6 blockade could reduce mortality in severe COVID-19, yet IL-6 is only modestly elevated in most patients. Chen et al. describe the role of soluble interleukin-6 receptor (sIL-6R) in IL-6 trans-signaling and how
Luke Y. C. Chen, C. Biggs, S. Jamal, S. Stukas, C. Wellington, M. Sekhon   +5 more
semanticscholar   +1 more source

Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease [PDF]

Blood, 1991
Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways.
M, Jücker, H, Abts, W, Li, R, Schindler, H, Merz, A, Günther, C, von Kalle, M, Schaadt, T, Diamantstein, A C, Feller   +9 more
openaire   +3 more sources

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

International Journal of Antimicrobial Agents, 2020
Highlights • Pathogenesis of cytokine release syndrome (CRS) in severe COVID-19 patients.• Key role of interleukin-6 (IL-6) in CRS.• IL-6 receptor (IL-6R) antagonist tocilizumab suggested as a possible drug for severe COVID-19.
Chi Zhang, Zhao Wu, Jiawen Li, Hong Zhao, Guiqiang Wang   +4 more
semanticscholar   +1 more source